Media stories about Spectranetics (NASDAQ:SPNC) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectranetics earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.4691319816145 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Spectranetics (NASDAQ:SPNC) remained flat at $$38.45 during trading on Friday. The company has a current ratio of 1.92, a quick ratio of 1.43 and a debt-to-equity ratio of 7.61. Spectranetics has a 52 week low of $19.80 and a 52 week high of $38.55. The stock has a market capitalization of $1,680.00, a price-to-earnings ratio of -24.18 and a beta of 1.54.

TRADEMARK VIOLATION NOTICE: “Spectranetics (SPNC) Earns Media Sentiment Rating of 0.03” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/31/spectranetics-spnc-earns-media-sentiment-rating-of-0-03.html.

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Insider Buying and Selling by Quarter for Spectranetics (NASDAQ:SPNC)

Receive News & Stock Ratings for Spectranetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics and related stocks with our FREE daily email newsletter.